Thyrocare Technologies Ltd
NSE:THYROCARE

Watchlist Manager
Thyrocare Technologies Ltd Logo
Thyrocare Technologies Ltd
NSE:THYROCARE
Watchlist
Price: 956.15 INR -1.4% Market Closed
Market Cap: 50.6B INR
Have any thoughts about
Thyrocare Technologies Ltd?
Write Note

Thyrocare Technologies Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Thyrocare Technologies Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Thyrocare Technologies Ltd
NSE:THYROCARE
Current Portion of Long-Term Debt
â‚ą89.4m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Agarwal's Eye Hospital Ltd
BSE:526783
Current Portion of Long-Term Debt
â‚ą199.7m
CAGR 3-Years
39%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Current Portion of Long-Term Debt
â‚ą1B
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
Current Portion of Long-Term Debt
â‚ą145.3m
CAGR 3-Years
13%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Krsnaa Diagnostics Ltd
NSE:KRSNAA
Current Portion of Long-Term Debt
â‚ą221.9m
CAGR 3-Years
-14%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Metropolis Healthcare Ltd
NSE:METROPOLIS
Current Portion of Long-Term Debt
â‚ą780m
CAGR 3-Years
33%
CAGR 5-Years
241%
CAGR 10-Years
N/A
No Stocks Found

Thyrocare Technologies Ltd
Glance View

Market Cap
50.6B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
585.36 INR
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Thyrocare Technologies Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
89.4m INR

Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Current Portion of Long-Term Debt amounts to 89.4m INR.

What is Thyrocare Technologies Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
43%

Over the last year, the Current Portion of Long-Term Debt growth was 24%. The average annual Current Portion of Long-Term Debt growth rates for Thyrocare Technologies Ltd have been 43% over the past three years .

Back to Top